Author:
Zesiewicz Theresa A.,Wilmot George,Kuo Sheng-Han,Perlman Susan,Greenstein Patricia E.,Ying Sarah H.,Ashizawa Tetsuo,Subramony S.H.,Schmahmann Jeremy D.,Figueroa K.P.,Mizusawa Hidehiro,Schöls Ludger,Shaw Jessica D.,Dubinsky Richard M.,Armstrong Melissa J.,Gronseth Gary S.,Sullivan Kelly L.
Abstract
ObjectiveTo systematically review evidence regarding ataxia treatment.MethodsA comprehensive systematic review was performed according to American Academy of Neurology methodology.ConclusionsFor patients with episodic ataxia type 2, 4-aminopyridine 15 mg/d probably reduces ataxia attack frequency over 3 months (1 Class I study). For patients with ataxia of mixed etiology, riluzole probably improves ataxia signs at 8 weeks (1 Class I study). For patients with Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole probably improves ataxia signs at 12 months (1 Class I study). For patients with SCA type 3, valproic acid 1,200 mg/d possibly improves ataxia at 12 weeks. For patients with spinocerebellar degeneration, thyrotropin-releasing hormone possibly improves some ataxia signs over 10 to 14 days (1 Class II study). For patients with SCA type 3 who are ambulatory, lithium probably does not improve signs of ataxia over 48 weeks (1 Class I study). For patients with Friedreich ataxia, deferiprone possibly worsens ataxia signs over 6 months (1 Class II study). Data are insufficient to support or refute the use of numerous agents. For nonpharmacologic options, in patients with degenerative ataxias, 4-week inpatient rehabilitation probably improves ataxia and function (1 Class I study); transcranial magnetic stimulation possibly improves cerebellar motor signs at 21 days (1 Class II study). For patients with multiple sclerosis–associated ataxia, the addition of pressure splints possibly has no additional benefit compared with neuromuscular rehabilitation alone (1 Class II study). Data are insufficient to support or refute use of stochastic whole-body vibration therapy (1 Class III study).
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference39 articles.
1. American Academy of Neurology. Clinical Practice Guidelines Process Manual. 2004 ed. St. Paul, MN: The American Academy of Neurology; 2004.
2. American Academy of Neurology. Clinical Practice Guideline Process Manual. 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.
3. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias;Strupp;Neurology,2011
4. Riluzole in cerebellar ataxia: A randomized, double-blind, placebo-controlled pilot trial
5. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial
Cited by
109 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献